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Abstract
How the immune system kills Mycobacterium tuberculosis is still a puzzle. The classical picture of killing due to phagocytosis by activated
macrophages may be only partly correct. Based on recent evidence, we express here the view that cytotoxic T lymphocytes also make an
important contribution and suggest that DNA vaccines might be a good way to enhance this. ß 2001 Federation of European Micro-
biological Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Mycobacterium tuberculosis is one of the most successful
bacterial parasites of humans, infecting over one-third of
the population of the world. This remarkable success is
because pathogenic mycobacteria can survive in the hostile
habitat of a macrophage, even in the face of a speci¢c T
cell immune response. As a result, a small number of via-
ble mycobacteria may persist at the site of infection. After
years of dormancy, this organism may start to replicate,
leading to the reactivation of infection and clinical disease.
Despite many years of research, the e¡ector mechanisms
by which M. tuberculosis is killed, when the immune re-
sponse mounts its most successful form of defence, remain
contentious. Bacteriostasis is the most prominent feature
of immunity, and is essential in the absence of e¡ective
bactericidal processes, but it probably also contributes to
bacterial dormancy and persistence. Stronger bactericidal
processes would be preferred in order to minimize the
problems posed by reactivation of dormant infection
many years later.
Adoptive transfer experiments have established beyond
doubt that protection is cell-mediated and not antibody-
mediated in tuberculosis. However, the evidence that pro-
tection requires activation of macrophages by antigen-spe-
ci¢c T lymphocytes so that the macrophages acquire an
ability to kill the mycobacteria remains less than com-
pelling. New evidence suggests that cytotoxic T cells may
also directly kill the bacteria, depending on the ability to
deliver potent bactericidal proteins such as granulysin
from their granules. Elucidation of the host^pathogen in-
teractions involved during the disease process is critical to
the development of new antimycobacterial treatment op-
tions. The development of new strategies to inhibit myco-
bacterial pathogenesis or augment the host response
against mycobacteria is crucial in order to curtail this
global health crisis. Here we discuss that a DNA vaccine
used therapeutically provides a new means of exploring
these processes showing its ability to induce the immune
system to kill both actively multiplying and dormant bac-
teria.
2. Pathogenesis and the role of macrophages
M. tuberculosis infections are acquired through inhala-
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tion of infective bacilli. Bacteria are internalized by alveo-
lar macrophages and set up infection foci in the lung tis-
sue. These foci expand through bacterial growth and re-
cruitment of macrophages and lymphocytes that build the
granuloma that de¢nes this infection. The granuloma
seems to support limited bacterial growth and prevents
metastasis of the infection. Nonetheless, the granuloma
also protects the bacterium from the immune response
and is probably responsible for the persistent or latent
nature of the infection. Clinical disease develops when
this immune-mediated constriction is abrogated through
immune compromise. Even in individuals in whom infec-
tion is controlled at the granulomatous state or earlier,
any later imbalance of the host’s immune system may
promote reactivation of the disease.
Macrophages play a multiplicity of roles in tuberculosis
including antigen processing and presentation and e¡ector
cell functions. Amongst the best characterized antimicro-
bial e¡ector functions of macrophages are lysosomal en-
zymes that are delivered to the phagosome during phago-
some^lysosome fusion, the generation of reactive oxygen
intermediates (ROIs) by the oxidative burst, the produc-
tion of reactive nitrogen intermediates (RNIs) and apopto-
sis [1].
Recently, two transgenic murine models of chronic
granulomatous disease have been developed. These trans-
genic mice are de¢cient in gp91phox or p47phox, phago-
some oxidase components critical for the activity or as-
sembly of the functional oxidase, respectively [2,3].
Cooper et al. [4] reported 10-fold higher bacterial numbers
in the lungs of p47phox knockout mice, compared to wild-
type controls, after aerosol challenge with M. tuberculosis.
These ¢ndings provide evidence that ROI-mediated con-
trol is important early during infection. In particular, they
are consistent with a role for ROIs in host defense against
M. tuberculosis prior to the emergence of interferon-Q
(IFN-Q)-mediated macrophage activation, nitric oxide
(NO) production and phagosome acidi¢cation. However,
M. tuberculosis has evolved strategies to avoid oxidative
killing mechanisms. For example, CR1- or CR3-dependent
uptake does not trigger the oxidative burst [5]. Mycobac-
teria also produce catalase and superoxide dismutase, two
gene products capable of degrading reactive oxygen spe-
cies [6], and de¢ciency in the katG gene encoding the my-
cobacterial catalase results in increased susceptibility to
peroxidative killing [7].
IFN-Q is now known to be essential for protection [8]
and is produced by CD4 T cells, CD8 T cells, NK cells
and the M. tuberculosis-infected macrophage itself [9]. The
importance of IFN-Q is demonstrated by the high suscep-
tibility to mycobacterial infections of patients with defec-
tive IFN-Q receptors [10]. A major factor of IFN-Q and
other Th1 cytokines in the antituberculous host response
is their macrophage activating and recruiting properties.
This could be largely due to its role in activating macro-
phages for mycobacteriostasis [11,12], rather than for kill-
ing, but it also impacts on many other aspects of immunity
besides macrophage activation [13]. Similarly, there is
compelling evidence for the importance of macrophage
NO in protection [14,15], but this might be more due to
a regulatory function of this key intracellular signaling
agent [16,17], upstream of the actual lethal events, rather
than due to direct toxicity of NO for the bacteria. How-
ever, there is evidence that RNIs do play an important
role in controlling M. tuberculosis infection in the murine
model [18]. At an in vivo level iNOS gene knockout mice,
that are de¢cient in mounting a RNI response, exhibit
chronic disease when infected with M. tuberculosis, in
comparison to control mice [19]. Moreover, treatment of
M. tuberculosis-infected mice with the iNOS inhibitor (L-
NMMA) has also been shown to increase bacterial bur-
den, tissue damage and mortality [18]. Recently, however,
con£icting reports suggesting that RNIs are not bene¢cial
in the murine response against mycobacteria have emerged
[20] showing that the iNOS gene knockout mice has in-
creased levels of IFN-Q in serum, increased granuloma
formation and increased survival of CD4 T cells. Also,
the actual production of NO by human macrophages re-
mains a controversial issue. Previously it was thought that
human macrophages did not produce NO and that this
accounted for their general inability to control infection
with virulent mycobacteria in contrast to mice that are
innately resistant. However, with the onset of new and
improved molecular technology, many reports have
emerged discounting this theory [21]. Notwithstanding
the controversy regarding the role of NO in mice or hu-
man host defence against tuberculosis, it seems highly
likely that other macrophage antimycobacterial e¡ector
mechanisms are involved, since many reports show re-
duced viability of M. tuberculosis within human macro-
phages that are not a¡ected by NO inhibitors [22]. Thus,
we can question, in fact, whether active killing by macro-
phages has a major role in either the initial arrest of bac-
terial population growth or in the subsequent slow decline
in population.
It seems likely that appropriately activated macrophages
can indeed sometimes kill virulent M. tuberculosis [23,24]
but that this is not usually su⁄cient for sterilizing immun-
ity. E¡ects seen in vitro are generally modest and the
target is clearly a di⁄cult one for macrophages to kill.
Extensive e¡orts have produced only sporadic claims to
demonstrate substantial killing and independent con¢rma-
tory evidence is sparse, particularly for human cells [25].
Possibly the right combination and sequence of di¡eren-
tiation and activation signals and a high rate of replace-
ment of expended macrophages occur in vivo, particularly
in the high turnover granulomas characterizing the earlier
stages of the immune response [1]. This might give major
and sustained bactericidal action but has not yet been
reproduced in vitro.
FEMSLE 9861 26-3-01 Cyaan Magenta Geel Zwart
C.L. Silva et al. / FEMS Microbiology Letters 197 (2001) 11^1812
 by guest on June 1, 2016
http://fem
sle.oxfordjournals.org/
D
ow
nloaded from
 
3. Which T cells confer protection?
Although adoptive transfer of protection with T lym-
phocytes from infected or immunized rats into naive ani-
mals established over 20 years ago that acquired immunity
against tuberculosis is cell-mediated [26], attempts to de-
¢ne the phenotype and function of the protective T cells
have given con£icting results. CD4, CD8, CD1-re-
stricted and QN-TCR T cells have all been implicated, as
have IFN-Q and cytotoxicity, without establishing how
they actually contribute to protection [27]. The importance
of the T cell response was also illustrated by Doherty and
Sher [28], who reported that athymic nude mice, which
have no mature T cells due to defective formation of the
thymic stroma, show a similar pattern of increased suscep-
tibility to mycobacterial infection to that of SCID (severe
combined immunode¢ciency) mice, in which neither anti-
body nor T cell responses are made. The importance of the
CD4 subset of T cells in antituberculous immunity is
seen in HIV patients, in which depleted CD4 T cell num-
bers correlate with extreme susceptibility to tuberculosis.
The protective CD4 T cell response in active tuberculosis
in humans is of the Th1 type and demonstrates the char-
acteristic Th1 cytokine pro¢le (secretion of IFN-Q, IL-12,
IL-2 and TNF-K) [29]. Thus, the accepted paradigm has
been that protection is mainly due to antigen-speci¢c
CD4 Th1 cells that produce IFN-Q to activate macro-
phages that then kill the mycobacteria during phagocyto-
sis. Bacteria that are not killed by this process have their
multiplication inhibited inside IFN-Q-activated macro-
phages. A subsidiary function is then served by cytotoxic
CD8 T cells that release intracellular bacteria from in-
fected cells so that they can be killed during phagocytosis
by activated macrophages [11] (Fig. 1). Even allowing for
some crossover between the activating and cytotoxic func-
tions of CD4 and CD8 T cells, it is now clear that this
is not the whole story. How do these T cells really function
in protection? First, there is general agreement that acti-
vation of antimicrobial activities in macrophages by T cell
cytokines is involved. Accordingly, IFN-Q, which is a ma-
jor macrophage activating cytokine, and other Th1 cyto-
kines are critical as stated above. Second, direct killing of
mycobacteria by T cells has been demonstrated. Third,
mycobacteria-reactive T cells lyse infected macrophages.
Macrophage lysis appears to be a prerequisite for killing
by T cells of microbes residing inside macrophages. More-
Fig. 1. The basic traditional view of the expression of acquired protective immunity against tuberculosis. The bacteria that are engulfed by monocytes
and tissue macrophages prior to the onset of the speci¢c immune response are able to multiply within those cells. When speci¢cally sensitized T cells ar-
rive, they release large amounts of IFN-Q on contact with antigen that is appropriately presented on cell surfaces. IFN-Q cannot activate the infected
cell for killing, only for bacteriostasis, but it is able, probably in conjunction with other factors, to activate freshly arriving monocytes su⁄ciently to
kill M. tuberculosis during phagocytosis. Killing may involve discharge of toxic macrophage products such as superoxide, NO and granule (lysosome)
contents into the phagocytic vesicle. The bacteria are made available for phagocytic killing through lysis of the infected macrophages by antigen-speci¢c
cytotoxic T cells. Abbreviations: IFN-Q, interferon-Q ; CD4, T cell di¡erentiated to CD4 and release of a type 1 cytokine pro¢le (Th1) on recognition
of antigen; CD8, T cell di¡erentiated to CD8 and expression of cytotoxicity (Tc1) on recognition of antigen.
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over, lysis of infected macrophages could promote release
of mycobacteria from incapacited macrophages to more
pro¢cient monocytes.
Although CD4 T cells are considered as the major
source of IFN-Q, other T cell populations have also been
shown to produce this and other Th1 cytokines. Similarly,
CD8 T cells are mainly responsible for the killing activ-
ities although additional T cell sets, in particular CD1-
restricted T cells, can perform these functions [30,31].
This redundancy should not be misinterpreted as meaning
that a single T cell population would su⁄ce for protection.
These T cell populations di¡er in other capacities, includ-
ing antigen speci¢city, genetic restriction and activation
requirements. Hence, it appears unlikely that any one T
cell population could fully compensate for another.
Involvement of CD8 T cells in protective immunity
against tuberculosis has been recognized for some time
[32^34] although the antigen speci¢city and function of
these cells were not clear. More recently, gene-targeted
mice with disrupted expression of key immunologic func-
tions have provided new insights into the role of CD8 T
cells in host defence. When L2-m and TAP1 knockout
mice, which cannot generate CD8 T cells, were infected
with M. tuberculosis, this resulted in an exacerbated course
of infection [35,36]. Moreover CD8 T cells from lungs of
infected mice produced IFN-Q in response to recognition
of antigen presented by M. tuberculosis-infected dendritic
cells or macrophages [37]. Short-term culture of the lung T
cells from infected mice with infected dendritic cells re-
sulted in CD8 T cells capable of MHC class I-restricted
speci¢c lysis of macrophages infected with live, virulent M.
tuberculosis [38]. CD8 T cells from PPD-reactive human
subjects could also be expanded in vitro by macrophages
infected with M. tuberculosis or BCG [39]. These CD8 T
cells proliferated in response to live bacteria or mycobac-
terial antigens and produced IFN-Q. These data supported
the hypothesis that MHC class I-restricted CD8 T cells
are required for control of tuberculosis.
Recent studies also support the idea that stimulation of
the CD8 T cell population must be considered in vaccine
design against tuberculosis [40,41]. The discovery that im-
munization of mice with a single mycobacterial antigen
(65-kDa heat-shock protein; hsp65) could give substantial
protection against tuberculosis challenge [42,43] led to
analyses in which the diversity of antigens recognized by
T cells responding to M. tuberculosis was no longer a
variable. The key to eliciting protection was in the use
of immunization procedures favoring presentation as an
endogenous antigen. Thus, in vivo expression from retro-
viral vector-transfected bone marrow cells or from a trans-
fected macrophage-like cell line, or DNA vaccination of
muscle or skin, or intravenous cationic liposome delivery
of the protein were all e¡ective [44]. Endogenous antigen
favored responses from MHC class I-restricted CD8 T
cells. Adoptive transfer of protection with hsp65-speci¢c T
cell lines or clones raised from such immunized animals
showed that, individually, the most protective were indeed
CD8 cells, although CD4 and Q/N T cells also protected
and marked synergy occurred with all three types trans-
ferred together [45,46]. Protection partly re£ected the abil-
ity of the cells to produce IFN-Q ; IL-4 producing cells
were not protective and protection with IFN-Q producing
cells was decreased by administering antibody against
IFN-Q. However, the most protective CD4 and CD8
T cell clones also displayed antigen-speci¢c cytotoxicity
in vitro and selectively lysed macrophages that were in-
fected with M. tuberculosis [46,47]. This is consistent
with the view that cytotoxicity also has a positive role in
protection [11].
4. The microbicidal proteins of cytotoxic lymphocytes
Since killing by macrophages seems to be ine⁄cient we
should take note of the increasing evidence that some T
lymphocytes can directly kill the bacteria. Macrophages
may not even be the main source of bactericidal products
in protection against tuberculosis after all. Perhaps the
¢rst pointer in this direction came from evidence that in-
tracellular BCG could be killed when human monocytes
containing the bacteria were lysed by speci¢c lymphocytes
that induced apoptosis by releasing ATP [48,49]. Killing of
virulent M. tuberculosis has not been reported by this
mechanism and other inducers of apoptosis or necrosis
were ine¡ective. It has not been established what the toxic
factor is which is generated under these conditions. Sim-
ilarly, Oddo and associates [50] have reported that cyto-
toxic CD4 T lymphocytes from man killed virulent M.
tuberculosis when they lysed infected macrophages by the
Fas^FasL pathway. The bacteria were also killed when
apoptosis was induced with TNF-K, suggesting that the
lethal product came from the macrophage rather than
the lymphocyte.
An approach from a completely di¡erent direction by
Robert Modlin and co-workers [31] has recently revealed
the existence, in man, of categories of cytotoxic CD8 T
lymphocytes that deliver highly microbicidal proteins into
infected macrophages. In so doing, they kill virulent M.
tuberculosis. These lethal cells can either be conventionally
MHC class I-restricted or recognize lipophilic antigens (a
prominent feature of mycobacteria) presented on CD1
structures. Their essential feature is that they lyse the tar-
get macrophages by the granule-mediated perforin mech-
anism of apoptosis and co-deliver bactericidal proteins. In
contrast to the ¢ndings of the Meylan group [50], T cells
that lysed targets by the Fas^FasL pathway to apoptosis
were not bactericidal. A key mycobactericidal protein de-
livered by the T cells has been identi¢ed as granulysin,
present in the same granules with perforin [51]. This pro-
tein is also found in NK cell granules and has known
potent lethal action against a range of microorganisms
and tumor cells.
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The di¡erences in the ¢ndings between these various
studies may be due to di¡erences in the way that macro-
phages were prepared from peripheral blood monocytes.
These cells can proceed from being undi¡erentiated imma-
ture monocytes through into widely diverse forms, includ-
ing dendritic cells [52], in vivo and in vitro depending on
the environmental stimuli encountered. Cell adherence to
di¡erent surfaces and exposure to di¡erent cytokines prior
to apoptosis doubtless resulted in biochemically and func-
tionally di¡erent cells in these studies. Hence we hypothe-
size that in some di¡erentiated states the cells have a my-
cobactericidal potential that is mobilized during apoptosis,
perhaps through autolytic generation of toxic products
(Fig. 2A). In other states they do not and killing during
apoptosis then depends on delivery of the toxic agent by
the lymphocyte (Fig. 2B).
Despite the in vitro evidence from human cells, pub-
lished studies with genetically modi¢ed mice have failed
to support a role for cytotoxicity in protection against
tuberculosis. Immunity during the ¢rst few weeks of in-
fection was unimpaired in mice in which the genes for
either perforin or granzyme B (a cytotoxic granule pro-
tease that contributes to apoptosis) had been knocked out
[53]. Protection against BCG also appeared normal in Fas-
defective mice [54]. However, since there are multiple path-
ways of cytotoxicity and multiple lytic and cytotoxic pro-
teins in cytotoxic granules, some redundancy might be
expected. Furthermore, three research groups are reputed
to have evidence that, at later stages of infection, immun-
ity is impaired in perforin knockout mice [51]. Thus, on
balance, it seems likely that similar systems contribute to
protection in man and mouse but that the relative impor-
tance of each may di¡er at di¡erent stages of infection.
5. Implications for vaccines and immunotherapy
Although CD4 T cells play a major role in the build-
up of an optimal protective immune response against tu-
berculosis, CD8 T cells are needed as well. Thus, if cy-
totoxicity can make a contribution to protection, tuber-
culosis vaccines should be designed to promote this aspect
of cellular immunity, not just Th1 responses and macro-
phage activation. In particular, antigen-speci¢c delivery of
cytotoxic mycobactericidal proteins may be highly desir-
able. Unfortunately, little is currently known of the mech-
anisms of regulation of the development of cytotoxicity
[55], still less of the di¡erential development of cells ex-
pressing the Fas^FasL versus the perforin pathways. How-
ever, DNA vaccination seems pre-disposed to generate
responses with a strong bias towards cytotoxicity [56], in-
cluding the phenotype most protective against tuberculo-
sis. DNA vaccines actually generate antigens that are pre-
sented via endogenous and exogenous pathways and also,
Fig. 2. Two potential routes to concomitant killing of intracellular M. tuberculosis during the death of infected macrophages. Route A: lysis mediated
by most CD4 cytotoxic T lymphocytes (CTL). The crosslinking of Fas on the CTL and FasL on the target cell induces lysis of the infected cell but
does not a¡ect signi¢cantly the viability of the intracellular bacteria, characterizing as a bacteriostase. Route B: lysis mediated by most CD8 CTL.
M. tuberculosis-reactive CTLs recognize bacterial antigen on the surface of an infected cell. Granular contents gain access to the intracellular compart-
ment via the polyperforin pore. E¡ector molecules such as granulysin and granzymes can now exert their antimycobacterial activity and contribute to
the eradication of intracellular microbes.
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the induced cross-priming events where exogenous antigen
released by myocytes is taken up by antigen presenting
cells is an important mechanism for either stimulating
CD4 and CD8 T lymphocytes and B cells to produce
antibodies. Huygen et al. [41] have recently shown that a
highly active tuberculosis DNA vaccine protects CD4
knockout mice but is not protective in CD8 knockout
mice. This result suggests that DNA vaccine induced pro-
tective CD8 T cells. We have also found precursors of
the protective hsp65-speci¢c CD8/IFN-Q producing/cyto-
toxic/CD44hi phenotype to persist at elevated frequency in
spleens in parallel with persistence of protection for at
least 8 months after DNA vaccination [44]. This also oc-
curs after BCG vaccination, or during M. tuberculosis in-
fection, but then the persistent response is dominated by T
cells with the non-protective Th2 phenotype (IL-4 produc-
ing, CD44lo, non-cytotoxic) [47]. To better understand the
role of T cells in protection against tuberculosis we further
characterized 28 CD4 and 28 CD8 hsp65-speci¢c T cell
clones in vitro and in vivo and test whether lysis of
M. tuberculosis-infected target macrophages by these
clones can cause death of the bacteria by either the perfor-
in- or Fas^FasL-dependent pathway [57].
Strikingly, only the T cell clones using the granule-de-
pendent pathway showed clear evidence of killing intra-
cellular M. tuberculosis when they lysed infected macro-
phages [57]. Those clones using the Fas^FasL pathway
had small e¡ects, equivalent to bacteriostasis. These might
be partly attributable to discharge of the bacteria into the
less favorable growth environment provided by the tissue
culture medium and partly to activation of non-lysed mac-
rophages by IFN-Q. The close correlation between the de-
gree of killing and the granule content of the clone, and
the selective inhibition of killing by prior degranulation,
are consistent with killing by the granule contents [57].
The mechanism is likely to be similar to that which was
recently revealed in studies of human cells [51]. Thus the
granule enzyme perforin may lyse macrophage membranes
to allow access of potent microbicidal granule enzymes
such as granulysin to the target mycobacteria. Attempts
to identify the mycobactericidal agent in the mouse cells
are underway. The correlation between the ability of the
cytotoxic clones to protect against challenge with M. tu-
berculosis in vivo and the clone’s granule content is a
further indication that this mycobacterial killing mecha-
nism has a role in protective immunity. It may account
for the major component of the protective e¡ect of these
clones that was resistant to neutralization in vivo by in-
jection of antibody against IFN-Q [46]. Although others
found that knockout mice that do not express the perforin
gene did not have decreased resistance to the early stages
of tuberculosis [53,54], this defence mechanism may be
more important later in infection. Our high-dose intrave-
nous challenge model probably resembles late-stage rather
than early-stage tuberculosis.
It was also striking that most of the cells lysing targets
using the cytotoxic granule pathway were CD8 cells,
whereas most of cells that lysed targets using the Fas^
FasL pathway were CD4 cells. This suggests that cyto-
toxicity may generally serve di¡erent purposes in tuber-
culosis depending on whether it is triggered by endogenous
or exogenous antigen. Thus the cytotoxic CD8 T cells
may have a predominantly antimicrobial function against
this intracellular pathogen, whereas the cytotoxic CD4 T
cells may have a predominantly immunomodulatory role
in removing the cells that sustain immune ‘help’ by pre-
senting antigen on MHC class II [31]. However, this divi-
sion of labor is not absolute, since a minority of cytotoxic
CD4 clones used the granule pathway and a minority of
the CD8 clones used the Fas^FasL pathway. Further-
more, at least in studies of human T cells, lysis of infected
target macrophages by non-granule-dependent pathways
may sometimes have direct antimycobacterial e¡ects [48^
50] and non-MHC-restricted cells may contribute signi¢-
cantly to granule-dependent killing [51]. These diverse and
somewhat contradictory ¢ndings may re£ect the plasticity
of the target cells as stated above. Hence we hypothesize
that in some di¡erentiated states the cells have a myco-
bactericidal potential that is mobilized during apoptosis,
perhaps through autolytic generation of toxic products. In
other states they do not and bacterial killing during cytol-
ysis then depends on delivery of the toxic agent by the
lymphocyte.
6. Concluding remarks
In summary, several distinct bactericidal mechanisms
may operate in cellular immunity against tuberculosis.
Di¡erent mechanisms may feature at di¡erent stages of
infection, to kill both actively multiplying and dormant
bacteria, and cumulatively decrease the duration of persis-
tence of the infection. It is likely that both cytokines,
released in response to speci¢c antigens, and direct cell :cell
interactions modulate di¡erentiation of these mechanisms.
DNA vaccines used either preventive or therapeutically
provide a new means of exploring these processes and
may lead to practical vaccines or immunotherapy that
bring bactericidal rather than bacteriostatic mechanisms
to the fore. The clinical impact of such developments
could be substantial. A recent publication of our group
reported successful therapy of tuberculosis in mice by
treatment with a DNA construct encoding hsp65 antigen
[40]. For tuberculosis, these issues deserve some reconsid-
eration, one-third of the world population is already in-
fected with M. tuberculosis, and thus living with a time
bomb, so there is a su⁄ciently large group to be consid-
ered as targets for a post-infection immunotherapy. More-
over, with the increasing risk of multi-drug-resistant tuber-
culosis and co-infection with HIV and tuberculosis,
therapeutic vaccines may warrant speci¢c consideration.
It can also be argued that microbial stress proteins do
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not make good candidates as vaccines because of the im-
plication of the homologous mammalian proteins in auto-
immune diseases [58]. However, there are possible alterna-
tives to leaving these major antigens out of vaccines: the
epitopes involved might be readily engineered out of the
DNA, or the formulation and delivery might be selected to
direct the response away from a harmful type and towards
a bene¢cial one. Indeed, T cells recognizing mycobacterial
HSPs can either protect against or potentiate autoimmune
disease, depending on their phenotype [59]. It was recently
demonstrated that DNA vaccination with mycobacterial
hsp65 protected Lewis rats against induction of adjuvant
arthritis [60]. This may be the best approach in the long
run because, to the extent that an acquired immune re-
sponse depends on recognition of ‘altered self’ rather than
‘foreign’, essentially all antigens may have the potential for
autoimmune involvement.
Acknowledgements
This study was supported in part by Fundac°a‹o de Am-
paro a' Pesquisa do Estado de Sa‹o Paulo (FAPESP) and
Conselho Nacional de Desenvolvimento Cient|¤¢co e Tec-
nolo¤gico (CNPq).
References
[1] Adams, D.O. and Hamilton, T.A. (1992) Molecular basis of macro-
phage activation: diversity and its origins. In: The Macrophage
(Lewis, C.E. and McGee, J.O.D., Eds.), pp. 75^114. Oxford Univer-
sity Press.
[2] Pollock, J.D., Williams, D.A., Gi¡ord, M.A., Li, L.L., Du, X., Fish-
erman, J., Orkin, S.H., Doerschuk, C.M. and Dinauer, M.C. (1995)
Mouse model of X-linked chronic granulomatous disease, an inher-
ited defect in phagocyte superoxide production. Nat. Genet. 9, 202^
209.
[3] Jackson, S.H., Gallin, J.I. and Holland, S.M. (1995) The p47 phx
mouse knock-out model of chronic granulomatous disease. J. Exp.
Med. 182, 751^758.
[4] Cooper, A.M., Segal, B.H., Frank, A.A., Holland, S.M. and Orme,
I.A. (2000) Transient loss of resistance to pulmonary tuberculosis in
p47phox3=3 mice. Infect. Immun. 68, 1231^1234.
[5] Schlesinger, L.S., Bellinger-Kawahara, C.G., Payne, N.R. and Hor-
witz, M.A. (1990) Phagocytosis of Mycobacterium tuberculosis is
mediated by human monocyte complement receptors and comple-
ment component C3. J. Immunol. 144, 2771^2780.
[6] Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris,
D., Gordon, S.V., Einglmeir, K., Gas, S., Barry, C.E., Tekaia, F.,
Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R.,
Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Hol-
royd, S., Hornsby, T., Jagels, K. and Barrel, B.G. et al. (1998) Deci-
phering the biology of Mycobacterium tuberculosis from the complete
genome sequence. Nature 393, 537^544.
[7] Zhang, Y., Heym, B., Allen, B., Young, D. and Cole, S. (1992) The
catalase-peroxidase gene and isoniazid resistance of Mycobacterium
tuberculosis. Nature 358, 591^593.
[8] Flynn, J.L., Chan, J., Triebold, K.J., Dalton, D.K., Stewart, T.A.
and Bloom, B.R. (1993) An essential role for interferon Q in resistance
to Mycobacterium tuberculosis. J. Exp. Med. 178, 2249^2254.
[9] Fenton, M.J., Vermeulen, M.W., Kim, S., Burdick, M., Strieter,
R.M. and Kornfeld, H. (1997) Induction of Q interferon production
in human alveolar macrophages by Mycobacterium tuberculosis. In-
fect. Immun. 65, 5149^5156.
[10] Altare, F., durandy, A., lammas, D., Emile, J.F., Lamhamedi, S., Le
Deist, F., Drysdale, P., Jouanguy, E., Do⁄nger, R., Bernaudin, F.,
Jeppsson, O., Gollob, J.A., Meinl, E., Segal, A.W., Fischer, A., Ku-
mararatne, D. and Casanova, J.L. (1998) Impairment of mycobacte-
rial immunity in human interleukin-12 receptor de¢ciency. Science
280, 1432^1435.
[11] De Libero, G., Flesch, I. and Kaufmann, S.H.E. (1988) Mycobacte-
ria-reactive Lyt-2+ T cell lines. Eur. J. Immunol. 18, 59^66.
[12] Howard, A.D. and Zwilling, B.S. (1998) Cytokine production by
CD4 and CD8 T cells during the growth of Mycobacterium tuber-
culosis in mice. Clin. Exp. Immunol. 113, 443^449.
[13] Boehm, U., Klamp, T., Groot, M. and Howard, J.C. (1997) Cellular
responses to interferon-Q. Annu. Rev. Immunol. 15, 749^795.
[14] Chan, J., Tanaka, K., Carroll, D., Flynn, J. and Bloom, B.R. (1995)
E¡ects of nitric oxide synthase inhibitors on murine infection with
Mycobacterium tuberculosis. Infect. Immun. 63, 736^740.
[15] MacMicking, J.D., North, R.J., LaCourse, R., Mudgett, J.S., Shah,
S.K. and Nathan, C.F. (1997) Identi¢cation of nitric oxide synthase
as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA
94, 5243^5248.
[16] Benbernou, N., Esnault, S., Shin, H.C.K., Fekkar, H. and Guenou-
nou, M. (1997) Di¡erential regulation of IFN-Q, IL-10 and inducible
nitric oxide synthase in human T cells by cyclic AMP-dependent
signal transduction pathway. Immunology 91, 361^368.
[17] Arnold, W.P., Mittal, C.K., Katsuki, S. and Murad, F. (1977) Nitric
oxide activates guanylate cyclase and increases guanosine 3P :5P-cyclic
monophosphate levels in various tissue preparations. Proc. Natl.
Acad. Sci. USA 74, 3203^3207.
[18] Chan, J., Tanaka, K., Carroll, D., Flynn, J. and Bloom, B.R. (1995)
E¡ects of nitric oxide synthase inhibitors on murine infection with
Mycobacterium tuberculosis. Infect. Immun. 63, 736^740.
[19] Schuller-Levis, G.B., Levis, W.R., Ammazzalorso, M., Nosrati, A.
and Park, E. (1994) Mycobacterial lipoarabinomannan induces nitric
oxide and tumor necrosis factor K production in a macrophage cell
line: down regulation by taurine chloramines. Infect. Immun. 62,
4671^4674.
[20] Gomes, M.S., Flo¤rido, M., Pais, T.F. and Appelberg, R. (1999) Im-
proved clearance of Mycobacterium avium upon disruption of the
inducible nitric oxide synthase gene. J. Immunol. 162, 6734^6739.
[21] Nozaki, Y., Hasegawa, Y., Ichiyama, S., Nakashima, I. and Shimo-
kata, K. (1997) Mechanism of nitric oxide-dependent killing of My-
cobacterium bovis BCG in human alveolar macrophages. Infect. Im-
mun. 65, 3644^3647.
[22] Rockett, K.A., Brookes, R., Udalova, I., Vital, V., Hill, A.V. and
Kwiatkowski, D. (1998) 1,25-Dihydroxyvitamin D3 induces nitric
oxide synthase and suppress growth of Mycobacterium tuberculosis
in a human macrophage-like cell line. Infect. Immun. 66, 5314^5321.
[23] Chan, J., Xing, Y., Magliozzo, R.S. and Bloom, B.R. (1992) Killing
of virulent Mycobacterium tuberculosis by reactive nitrogen inter-
mediates produced by activated murine macrophages. J. Exp. Med.
175, 1111^1122.
[24] Sato, K., Akaki, T. and Tomioka, H. (1998) Di¡erential potentiation
of anti-mycobacterial activity and reactive nitrogen intermediate-pro-
ducing ability of murine peritoneal macrophages activated by inter-
feron-Q (IFN-Q) and tumour necrosis factor-K (TNF-K). Clin. Exp.
Immunol. 112, 63^68.
[25] Warwick-Davies, J., Dhillon, J., O’Brien, L., Andrew, P.W. and
Lowrie, D.B. (1994) Apparent killing of Mycobacterium tuberculosis
by cytokine-activated human monocytes can be an artefact of a cy-
totoxic e¡ect on the monocytes. Clin. Exp. Immunol. 96, 214^217.
[26] Le¡ord, M.J., McGregor, D.D. and Mackaness, G.B. (1973) Immune
response to Mycobacterium tuberculosis in rats. Infect. Immun. 8,
182^189.
FEMSLE 9861 26-3-01 Cyaan Magenta Geel Zwart
C.L. Silva et al. / FEMS Microbiology Letters 197 (2001) 11^18 17
 by guest on June 1, 2016
http://fem
sle.oxfordjournals.org/
D
ow
nloaded from
 
[27] Harboe, M., Andersen, P., Colston, M.J., Gicquel, B., Hermans,
P.W., Ivanyi, J. and Kaufmann, S.H. (1996) European Commission
COST/STD Initiative. Report of the expert panel IX. Vaccines
against tuberculosis. Vaccine 14, 701^716.
[28] Dohert, T.M. and Sher, A. (1997) Defects in cell-mediated immunity
a¡ect chronic, but not innate resistance of mice to Mycobacterium
avium infection. J. Immunol. 158, 4822^4831.
[29] Barnes, P.F., Abrams, J.S., Lu, S., Sieling, P.A., Rea, T.H. and
Modlin, R.L. (1993) Patterns of cytokine production by Mycobacte-
rium tuberculosis-reactive human T cell clone. Infect. Immun. 61,
197^203.
[30] Rosat, J.P., Grant, E.P., Beckman, E.M., Dascher, C.C., Sieling,
P.A., Frederique, D., Modlin, R.L., Porcelli, S.A., furlong, S.T.
and Brenner, M.B. (1999) CD1-restricted microbial lipid antigen-spe-
ci¢c recognition found in the CD8 KL T cell pool. J. Immunol. 162,
366^373.
[31] Stenger, S., Mazzaccaro, R., Uymura, K., Cho, S., Barnes, P., Rosat,
J., Sette, A., Brenner, M., Porcelli, S., Bloom, B. and Modlin, R.
(1997) Di¡erential e¡ects of cytolytic T cell subsets on intracellular
infection. Science 276, 1684^1687.
[32] Orme, I.M. (1987) Aging and immunity to tuberculosis : increased
susceptibility of old mice re£ects a decreased capacity to generate
mediator T lymphocytes. J. Immunol. 138, 293^298.
[33] Tan, J.S., Canaday, D.H., Bloom, W.H., Balaji, K.N., Schwander,
S.K. and Rick, E.A. (1997) Human alveolar T lymphocyte responses
to Mycobacterium tuberculosis antigen: role for CD4 and CD8
cytotoxic T cells and relative resistance of alveolar macrophages to
lysis. J. Immunol. 159, 290^297.
[34] Lewinsohn, D.M., Alderson, m.R., Briden, A.L., Riddell, S.R., Reed,
S.G. and Grabstein, K.H. (1998) Characterization of human CD8 T
cells reactive with Mycobacterium tuberculosis-infected antigen pre-
senting cells. J. Exp. Med. 187, 1633^1640.
[35] Flynn, J.L., Goldstein, M.M., Triebold, K.J., Koller, B. and Bloom,
B.R. (1992) Major histocompatibility complex class I-restricted T
cells are required for resistance to Mycobacterium tuberculosis infec-
tion. Proc. Natl. Acad. Sci. USA 89, 12013^12017.
[36] Behar, S.M., Dascher, C.C., Grusby, M.J., Wang, C.R. and Brenner,
M.B. (1999) Susceptibility of mice de¢cient in CD 1D or TAP1 to
infection with Mycobacterium tuberculosis. J. Exp. Med. 189, 1973^
1980.
[37] Serbina, N.V. and Flynn, J.L. (1999) Early emergence of CD8 T
cells primed for production of type 1 cytokines in the lungs of My-
cobacterium tuberculosis-infected mice. Infect. Immun. 67, 3980^3988.
[38] Serbina, N.V., Liu, C.C., Scanga, C.A. and Flynn, J.L. (2000) CD8
cytotoxic T lymphocytes from lungs of Mycobacterium tuberculosis
infected mice express perforin in vivo and lyse infected macrophages.
J. Immunol. 165, 353^363.
[39] Smith, S.M., Malin, A.S., Lukey, P.T., Atkinson, S.E., Content, J.,
Huygen, K. and Dockrell, H.M. (1999) Characterization of human
Mycobacterium bovis bacilli-Clamette-Guerin-reactive CD8 T cells.
Infect. Immun. 67, 5223^5230.
[40] Lowrie, D.B., Tascon, R.E., Bonato, V.L., Lima, V.M., Faccioli,
L.H., Stavropoulos, E., Colston, M.J., Hewinson, R.G., Moelling,
K. and Silva, C.L. (1999) Therapy of tuberculosis in mice by DNA
vaccination. Nature 400, 269^271.
[41] Huygen, K., Content, J., Dennis, D.L., Montgomery, D.L., Yawman,
A.M., Deck, R.R., De Witt, C.M., Orme, I.M., Baldwin, S., D’Sou-
za, C., Drowart, A., Lozes, E., Van denbussche, P., Van Vooren, J.P.,
Liu, M.A. and Ulmer, J.B. (1996) Immunogenicity and protective
e⁄cacy of a tuberculosis DNA vaccine. Nat. Med. 2, 893^898.
[42] Silva, C.L. and Lowrie, D.B. (1994) A single mycobacterial protein
(hsp65) expressed by a transgenic antigen-presenting cell vaccinates
mice against tuberculosis. Immunology 82, 244^248.
[43] Tascon, R.E., Colston, M.J., Ragno, S., Stavropoulos, E., Gregory,
D. and Lowrie, D.B. et al. (1996) Vaccination against tuberculosis by
DNA injection. Nat. Med. 2, 888^892.
[44] Silva, C.L., Pietro, R.C.L.R., Janua¤rio, A., Bonato, V.D.L., Lima,
V.M.F., Silva, M.F. and Lowrie, D.B. (1995) Protection against tu-
berculosis by bone marrow cells expressing mycobacterial hsp65. Im-
munology 86, 519^524.
[45] Silva, C.L., Silva, M.F., Pietro, R.C.L.R. and Lowrie, D.B. (1994)
Protection against tuberculosis by passive transfer with T cell clones
recognizing mycobacterial heat-shock protein 65. Immunology 83,
341^346.
[46] Silva, C.L., Silva, M.F., Pietro, R.C.L.R. and Lowrie, D.B. (1996)
Characterization of the T cells that confer a high degree of protective
immunity against tuberculosis in mice after vaccination with tumour
cells expressing mycobacterial hsp65. Infect. Immun. 64, 2400^2407.
[47] Bonato, V.L.D., Lima, V.M.F., Tascon, R.E., Lowrie, D.B. and Sil-
va, C.L. (1998) Identi¢cation and characterization of protective T
cells in hsp65 DNA vaccinated and Mycobacterium tuberculosis in-
fected mice. Infect. Immun. 66, 169^175.
[48] Molloy, A., Laochumroonvorapong, P. and Kaplan, G. (1994) Apo-
ptosis, but not necrosis, of infected monocytes is coupled with killing
of intracellular bacillus Calmette-Gue¤rin. J. Exp. Med. 180, 1499^
1509.
[49] Lammas, D.A., Stober, C., Harvey, C.J., Kendrick, N., Panchalin-
gam, S. and Kumararatne, D.S. (1997) ATP-induced killing of my-
cobacteria by human macrophages is mediated by purinergic
P2Z(P2X(7)) receptors. Immunity 7, 433^444.
[50] Oddo, M., Renno, T., Attinger, A., Bakker, T., MacDonald, H.R.
and Meylan, P.R. (1998) Fas ligand-induced apoptosis of infected
human macrophages reduces the viability of intracellular Mycobacte-
rium tuberculosis. J. Immunol. 160, 5448^5454.
[51] Stenger, S., Hanson, D.A., Teitelbaum, R., Dewan, P., Niazi, K.R.,
Froelich, C.J., Ganz, T., ThomaUszynski, S., Melian, A., Bogdan,
C., Porcelli, S.A., Bloom, B.R., Krensky, A.M. and Modlin, R.L.
(1998) An antimicrobial activity of cytolytic T cells mediated by
granulysin. Science 282, 121^125.
[52] Zhou, L.J. and Tedder, T.F. (1996) CD14(+) blood monocytes can
di¡erentiate into functionally mature CD83(+) dendritic cells. Proc.
Natl. Acad. Sci. USA 93, 2588^2592.
[53] Cooper, A.M., D’Souza, C., Frank, A.A. and Orme, I.M. (1997) The
course of Mycobacterium tuberculosis infection in the lungs of mice
lacking expression of either perforin- or granzyme-mediated cytolytic
mechanisms. Infect. Immun. 65, 1317^1320.
[54] Laochumroonvorapong, P., Wang, J., Liu, C.C., Moreira, A.L., El-
kon, K.B., Freedman, V.H. and Kaplan, G. (1997) Perforin, a cyto-
toxic molecule which mediates cell necrosis, is not required for the
early control of mycobacterial infection in mice. Infect. Immun. 65,
127^132.
[55] Lanzavecchia, A. (1998) Immunology. Licence to kill. Nature 393,
413^414.
[56] Iwasaki, A., Torres, C.A.T., Ohashi, P.S., Robinson, H.L. and Bar-
ber, B.H. (1997) The dominant role of bone marrow-derived cells in
CTL induction following plasmid DNA immunization at di¡erent
sites. J. Immunol. 159, 11^14.
[57] Silva, C.L. and Lowrie, D.B. (2000) Identi¢cation and characteriza-
tion of murine cytotoxic T cells that kill Mycobacterium tuberculosis.
Infect. Immun. 68, 3269^3274.
[58] Van Eden, W., Thole, J.E., Van Der Zee, R., Noordzij, A., Van
Emmbden, J.D., Hensen, E.J. and Cohen, I.R. (1988) Cloning of
the mycobacterial epitope recognized by T lymphocytes in adjuvant
arthritis. Nature 331, 171^173.
[59] Thompson, S.J., Francis, J.N., Khai Siew, L., Webb, G.R., Jenner,
P.J., Colston, M.J. and Elson, C.J. (1988) An immunodominant epi-
tope from mycobacterial 65-kDa heat shock protein protects against
pristine-induced arthritis. J. Immunol. 160, 4628^4634.
[60] Ragno, S., Colston, M.J., Lowrie, D.B., Winrow, V.R., Blake, D.R.
and Tascon, R. (1997) Protection of rats from adjuvant arthritis by
immunization with naked DNA encoding for mycobacterial heat
shock protein 65. Arthritis Rheum. 40, 277^283.
FEMSLE 9861 26-3-01 Cyaan Magenta Geel Zwart
C.L. Silva et al. / FEMS Microbiology Letters 197 (2001) 11^1818
 by guest on June 1, 2016
http://fem
sle.oxfordjournals.org/
D
ow
nloaded from
 
